ImmuPharma PLC (IMM) — Net Asset Quality Index
ImmuPharma PLC (IMM) has a Net Asset Quality Index of 21.3% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of GBX1.58 Million minus total liabilities of GBX1.24 Million yields net assets of GBX336.70K. A higher index indicates a stronger, lower-leverage balance sheet. Check ImmuPharma PLC (IMM) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
ImmuPharma PLC Net Asset Quality Index Over Time (2004–2024)
This chart shows how ImmuPharma PLC's Net Asset Quality Index has evolved across 22 annual periods from 2004 to 2024. As of June 2025, the index stands at 21.3%, representing net assets of GBX336.70K against total assets of GBX1.58 Million GBX. See IMM current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for ImmuPharma PLC (2004–2024)
The table below presents the year-by-year Net Asset Quality Index for ImmuPharma PLC from 2004 to 2024, covering 22 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of ImmuPharma PLC.
| Year | Quality Index | Net Assets (GBX) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | -55.6% | GBX-542.86K | GBX977.01K | GBX1.52 Million | ▼ -94.4 pp |
| 2023 | 38.8% | GBX1.06 Million | GBX2.72 Million | GBX1.67 Million | ▼ -24.7 pp |
| 2022 | 63.5% | GBX2.52 Million | GBX3.97 Million | GBX1.45 Million | ▼ -10.1 pp |
| 2021 | 73.6% | GBX4.41 Million | GBX6.00 Million | GBX1.58 Million | ▼ -14.9 pp |
| 2020 | 88.4% | GBX9.65 Million | GBX10.92 Million | GBX1.26 Million | ▼ -2.4 pp |
| 2019 | 90.8% | GBX5.27 Million | GBX5.80 Million | GBX531.87K | ▲ +2.8 pp |
| 2018 | 88.0% | GBX7.62 Million | GBX8.66 Million | GBX1.03 Million | ▲ +16.8 pp |
| 2017 | 71.2% | GBX3.57 Million | GBX5.02 Million | GBX1.44 Million | ▼ -11.4 pp |
| 2016 | 82.7% | GBX5.55 Million | GBX6.71 Million | GBX1.16 Million | ▲ +30.0 pp |
| 2015 | 52.6% | GBX1.69 Million | GBX3.21 Million | GBX1.52 Million | ▼ -28.1 pp |
| 2014 | 80.7% | GBX5.71 Million | GBX7.07 Million | GBX1.37 Million | ▲ +5.7 pp |
| 2013 | 75.0% | GBX5.40 Million | GBX7.21 Million | GBX1.80 Million | ▼ -5.1 pp |
| 2012 | 80.1% | GBX8.42 Million | GBX10.51 Million | GBX2.09 Million | ▼ -7.5 pp |
| 2011 | 87.6% | GBX12.51 Million | GBX14.28 Million | GBX1.77 Million | ▼ -3.4 pp |
| 2010 | 91.0% | GBX15.97 Million | GBX17.55 Million | GBX1.58 Million | ▲ +17.6 pp |
| 2009 | 73.4% | GBX18.08 Million | GBX24.64 Million | GBX6.56 Million | ▼ -10.5 pp |
| 2008 | 83.9% | GBX11.24 Million | GBX13.40 Million | GBX2.16 Million | ▲ +9.5 pp |
| 2007 | 74.4% | GBX3.05 Million | GBX4.10 Million | GBX1.05 Million | ▼ -6.0 pp |
| 2006 | 80.4% | GBX5.89 Million | GBX7.33 Million | GBX1.44 Million | ▲ +11.3 pp |
| 2006 | 69.0% | GBX2.50 Million | GBX3.63 Million | GBX1.12 Million | ▼ -29.6 pp |
| 2005 | 98.6% | GBX993.00K | GBX1.01 Million | GBX14.00K | ▼ -1.2 pp |
| 2004 | 99.8% | GBX978.00K | GBX980.00K | GBX2.00K | — |